Evidence map›Paper›PMID 37275938›Full record

ReviewWorld journal of clinical oncology2023

Tyrosine kinase inhibitors and human epidermal growth factor receptor-2 positive breast cancer.

Aya Abunada, Zaid Sirhan, Anita Thyagarajan, Ravi P Sahu

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Aya AbunadaDepartment of Pharmacy, Sidra Medicine, Doha 0000, Qatar.
Zaid SirhanDepartment of Pharmacology and Toxicology, Boonshoft School of Medicine Wright State University, Dayton, OH 45435, United States.
Anita ThyagarajanDepartment of Pharmacology and Toxicology, Boonshoft School of Medicine Wright State University, Dayton, OH 45435, United States.
Ravi P SahuDepartment of Pharmacology and Toxicology, Boonshoft School of Medicine Wright State University, Dayton, OH 45435, United States. ravi.sahu@wright.edu.
Wright State University · USQatar Airways (Qatar) · QA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The body of evidence investigating human epidermal growth factor receptor-2 (HER2) directed therapy in patients with breast cancer (BC) has been growing within the last decade. Recently, the use of tyrosine kinase inhibitors (TKIs) has been of particular interest in the treatment of human malignancies. This literature commentary is intended to highlight the most recent findings associated with the widely-studied TKI agents and their clinical significance in improving the outcomes of HER2 positive BC.

Indexed as

Human epidermal growth factor receptor-2 positive breast cancerLapatinibPyrotinibTrastuzumabTucatinibTyrosine kinase inhibitors

Identifiers

PMID37275938
PMCPMC10236985
OpenAlexW4377097586

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.